Hometown Urgent Care in Ohio is one of just 18 sites participating in a new phase 3 clinical trial to assess a prospective treatment for adult patients with acute migraines. The trial will compare pain freedom in subjects who’ve taken the drug rimegepant vs placebo in the acute treatment of migraine at 2 hours postdose. It will also take into account freedom from the “most bothersome symptom” (nausea, phonophobia, or photophobia) in the rimegepant group vs the placebo group at 2 hours postdose. Around 850 subjects have been enrolled in the trial, which is sponsored by Biohaven Pharmaceutical Holding Company, Ltd. Subjects are patients ≥18 years of age who have at least a 1-year history of migraines as defined by the International Classification of Headache Disorder, 3rd edition. Readers of JUCM News may recall that Hometown Urgent Care has taken part in more than 125 clinical trials in areas including gastroenterology, respiratory, pain management, family medicine, infections disease, and various acute conditions. With a database of over 374,000 patients, it is well positioned to quickly assess its capabilities to enroll subjects.
Published on
Phase 3 Migraine Clinical Trial Finds a Prime Site in Urgent Care